Literature DB >> 8755752

Surgical outcome after repeated transsphenoidal surgery in acromegaly.

H Long1, H Beauregard, M Somma, R Comtois, O Serri, J Hardy.   

Abstract

Transsphenoidal selective adenomectomy is the most efficient primary treatment for acromegaly. However, management of persistent or recurrent disease remains controversial. The objective of the present study was to evaluate the early and long-term efficacy and safety of a second transsphenoidal surgery performed in those cases. The results of a retrospective study of 16 patients undergoing reoperation by the senior author (J.H.) between 1970 and 1991 are reported. Reoperation was performed for persistent or progressive acromegaly in 11 patients, visual impairment in four, and disease recurrence in one. Normalization of growth hormone (GH) was defined as a basal GH level of less than 5 micrograms/L and suppression to less than 2 micrograms/L during the oral glucose tolerance test. Long-term follow-up data were available in 15 patients. The second transsphenoidal surgery induced a greater than 50% decrease of GH level in 11 patients. Three (19%) of 16 patients were cured according to the authors' criteria and remained so after 2, 7, and 20 years. Two more patients had a postoperative basal GH level of less than 5 micrograms/L but incomplete suppression during the oral glucose tolerance test. Thus, a total of five patients (31%) achieved a basal GH of less than 5 micrograms/L. One other patient who had no initial improvement after the second transphenoidal surgery had spontaneous normalization of his GH level after 13 years. The following complications of the second surgery occurred in three patients: one subarachnoid hemorrhage, two new visual field defects, one cranial nerve palsy, and one meningitis. Moreover, 10 patients (62.5%) developed one or more new pituitary hormone deficiencies. In conclusion, reoperation for persistent or recurrent acromegaly has low success and high complication rates. According to the authors' experience, this procedure should be reserved for patients unresponsive to other forms of therapy or with progressive visual impairment despite medical therapy.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8755752     DOI: 10.3171/jns.1996.85.2.0239

Source DB:  PubMed          Journal:  J Neurosurg        ISSN: 0022-3085            Impact factor:   5.115


  16 in total

Review 1.  Treatment of pituitary tumors: surgery.

Authors:  Michael Buchfelder
Journal:  Endocrine       Date:  2005-10       Impact factor: 3.633

2.  Endoscopic versus microscopic approach for surgical treatment of acromegaly.

Authors:  Hussein Fathalla; Michael D Cusimano; Antonio Di Ieva; John Lee; Omar Alsharif; Jeannette Goguen; Stanley Zhang; Harley Smyth
Journal:  Neurosurg Rev       Date:  2015-02-10       Impact factor: 3.042

3.  Endoscopic endonasal surgery for recurrent pituitary tumors: technical challenges to the surgical approach.

Authors:  Bobby A Tajudeen; Jagmeet Mundi; Jeffrey D Suh; Marvin Bergsneider; Marilene B Wang
Journal:  J Neurol Surg B Skull Base       Date:  2014-09-13

4.  Outcome of surgery for acromegaly performed by different surgeons: importance of surgical experience.

Authors:  Erdinc Erturk; Ercan Tuncel; Sinem Kiyici; Canan Ersoy; Cevdet Duran; Sazi Imamoglu
Journal:  Pituitary       Date:  2005       Impact factor: 4.107

Review 5.  Surgery induced hypopituitarism in acromegalic patients: a systematic review and meta-analysis of the results.

Authors:  Pedro Carvalho; Eva Lau; Davide Carvalho
Journal:  Pituitary       Date:  2015-12       Impact factor: 4.107

Review 6.  Management options for persistent postoperative acromegaly.

Authors:  Nestoras Mathioudakis; Roberto Salvatori
Journal:  Neurosurg Clin N Am       Date:  2012-08-09       Impact factor: 2.509

Review 7.  Modern treatment of acromegaly.

Authors:  Z Merza
Journal:  Postgrad Med J       Date:  2003-04       Impact factor: 2.401

8.  Effect of surgery and radiotherapy on visual and endocrine function in nonfunctioning pituitary adenomas.

Authors:  A Colao; G Cerbone; P Cappabianca; D Ferone; A Alfieri; F Di Salle; A Faggiano; B Merola; E de Divitiis; G Lombardi
Journal:  J Endocrinol Invest       Date:  1998-05       Impact factor: 4.256

Review 9.  Nanomedicines in the treatment of acromegaly: focus on pegvisomant.

Authors:  Ferdinand Roelfsema; Nienke R Biermasz; Alberto M Pereira; Johannes Romijn
Journal:  Int J Nanomedicine       Date:  2006

10.  Therapeutic options in the management of acromegaly: focus on lanreotide Autogel.

Authors:  Ferdinand Roelfsema; Nienke R Biermasz; Alberto M Pereira; Johannes A Romijn
Journal:  Biologics       Date:  2008-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.